BrainCells Inc., a company leading the scientific research of neurogenesis using its proprietary platform technology to identify novel pathways for the treatment of central nervous system (CNS) diseases, announced results from the first clinical proof-of-concept study of BCI-952, a combination of low dose buspirone and melatonin, for the treatment of major depressive disorder (MDD).
Popularity: 1% [?]
Related posts:
- BrainCells Inc. Initiates Phase 2 Clinical Trial With BCI-540 For Depression With Anxiety
- SPRI Clinical Trials Now Enrolling Patients For Study Of New Treatment For Depression
- Clinical Data, Inc. Announces Publication Of Results From First Phase III Study Of Vilazodone In Treatment Of Major Depressive Disorder
- Targacept’s TC-5214 Achieves All Primary And Secondary Outcome Measures In Phase 2b Trial As Augmentation Treatment For Major Depressive Disorder
- DOV Pharmaceutical, Inc. Initiates Phase II Clinical Trial In Patients With Major Depressive Disorder
Comments
No Responses to “Unlikely Treatment Identified By BrainCells Neurogenesis Platform Improved Clinical Outcomes In Patients Suffering From Depression”